HeartBeam (BEAT)
(Delayed Data from NSDQ)
$2.47 USD
+0.22 (9.78%)
Updated Sep 5, 2024 04:00 PM ET
After-Market: $2.48 +0.01 (0.40%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$2.47 USD
+0.22 (9.78%)
Updated Sep 5, 2024 04:00 PM ET
After-Market: $2.48 +0.01 (0.40%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Has BioTelemetry (BEAT) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (BEAT) Outperforming Other Medical Stocks This Year?
Zacks.com highlights: BioTelemetry, Ericsson, Intel, United States Cellular and Cigna
by Zacks Equity Research
Zacks.com highlights: BioTelemetry, Ericsson, Intel, United States Cellular and Cigna
The Zacks Analyst Blog Highlights: NetApp, Atkore International Group, Bio Telemetry, and Chefs' Warehouse
by Zacks Equity Research
The Zacks Analyst Blog Highlights: NetApp, Atkore International Group, Bio Telemetry, and Chefs' Warehouse
Mid-term Election to Propel Stocks Higher: 4 Picks
by Zacks Equity Research
Strong U.S. economy and other fundamentals could help stocks soar following the mid-term elections, making some stocks apt for investment.
5 Relative Price Strength Stocks to Maximize Your Returns
by Nilanjan Choudhury
Want to try an out-of-the-box approach to earn handsome returns? Tap these stocks with explosive relative price strength.
BioTelemetry (BEAT) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
BioTelemetry (BEAT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Earnings Estimates Rising for BioTelemetry (BEAT): Will It Gain?
by Zacks Equity Research
BioTelemetry (BEAT) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Near-Term Outlook for Medical Services Industry Looks Bright
by Urmimala Biswas
Growing importance of efficient healthcare management is positioning the providers of medical services well to benefit.
Is BioTelemetry (BEAT) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (BEAT) Outperforming Other Medical Stocks This Year?
BioTelemetry (BEAT) Q3 Earnings Preview: What to Look Out For
by Zacks Equity Research
BioTelemetry (BEAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Healthcare Arm Drive BioTelemetry's (BEAT) Q3 Earnings?
by Zacks Equity Research
Product launches, synergies from LifeWatch acquisition and favorable payor mix are expected to have worked in favor of BioTelemetry's (BEAT) Healthcare arm in Q3.
Is BioTelemetry (BEAT) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (BEAT) Outperforming Other Medical Stocks This Year?
Zacks Market Edge Highlights: Intuitive Surgical, BioTelemetry, Edwards Lifesciences, Penumbra and Vericel
by Zacks Equity Research
Zacks Market Edge Highlights: Intuitive Surgical, BioTelemetry, Edwards Lifesciences, Penumbra and Vericel
How to Invest in the Hot Medical Device Innovators
by Tracey Ryniec
Forget the biotechs. Medical device companies are innovating in amazing ways. Here's how to invest.
Is BioTelemetry (BEAT) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (BEAT) Outperforming Other Medical Stocks This Year?
Teladoc Leads Telehealth Thanks to its Virtual Care Solution
by Zacks Equity Research
Teladoc's (TDOC) vast product portfolio, client base, tie-ups and acquisitions make it a leader in the telehealth industry.
Zacks.com featured highlights include: Malibu Boats, BJ's, Group 1, Paycom and BioTelemetry
by Zacks Equity Research
Zacks.com featured highlights include: Malibu Boats, BJ's, Group 1, Paycom and BioTelemetry
Bet on These 5 Momentum Stocks Backed by Driehaus Strategy
by Zacks Equity Research
We have used the Driehaus' "buy high and sell higher" principle to choose the best momentum stocks.
Is BioTelemetry (BEAT) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (BEAT) Outperforming Other Medical Stocks This Year?
Here's Why BioTelemetry (BEAT) is a Great Momentum Stock
by Zacks Equity Research
Does BioTelemetry (BEAT) have what it takes to be a top stock pick for momentum investors? Let's find out.
Should First Trust Small Cap Growth AlphaDEX Fund (FYC) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FYC
Medical Services Boom Drives Healthcare: 3 Top Picks
by Sreyoshi Mukherjee
Considering the rising popularity of PBM, CRO and EHR in the U.S. Medical Services industry, these three picks might be money-spinning choices for investors.
Will BioTelemetry (BEAT) Gain on Rising Earnings Estimates?
by Zacks Equity Research
BioTelemetry (BEAT) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Is BioTelemetry (BEAT) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (BEAT) Outperforming Other Medical Stocks This Year?
Has BioTelemetry (BEAT) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (BEAT) Outperforming Other Medical Stocks This Year?